Literature DB >> 29100071

Cancer Evolution during Immunotherapy.

M C Andrews1, J A Wargo2.   

Abstract

Immune checkpoint blockade has revolutionized cancer treatment. In this issue of Cell, insights from a longitudinal multi-omics analysis of the largest yet-reported cohort of melanoma patients reveal how tumor and immunity co-evolve during anti-PD-1 therapy.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29100071      PMCID： PMC5755374          DOI： 10.1016/j.cell.2017.10.027

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  9 in total

1.  Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors:  Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal:  N Engl J Med       Date:  2014-11-19       Impact factor: 91.245

2.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Authors:  Pei-Ling Chen; Whijae Roh; Alexandre Reuben; Zachary A Cooper; Christine N Spencer; Peter A Prieto; John P Miller; Roland L Bassett; Vancheswaran Gopalakrishnan; Khalida Wani; Mariana Petaccia De Macedo; Jacob L Austin-Breneman; Hong Jiang; Qing Chang; Sangeetha M Reddy; Wei-Shen Chen; Michael T Tetzlaff; Russell J Broaddus; Michael A Davies; Jeffrey E Gershenwald; Lauren Haydu; Alexander J Lazar; Sapna P Patel; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Scott E Woodman; Luis M Vence; Ignacio I Wistuba; Rodabe N Amaria; Lawrence N Kwong; Victor Prieto; R Eric Davis; Wencai Ma; Willem W Overwijk; Arlene H Sharpe; Jianhua Hu; P Andrew Futreal; Jorge Blando; Padmanee Sharma; James P Allison; Lynda Chin; Jennifer A Wargo
Journal:  Cancer Discov       Date:  2016-06-14       Impact factor: 39.397

3.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

4.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.

Authors:  Whijae Roh; Pei-Ling Chen; Alexandre Reuben; Christine N Spencer; Peter A Prieto; John P Miller; Vancheswaran Gopalakrishnan; Feng Wang; Zachary A Cooper; Sangeetha M Reddy; Curtis Gumbs; Latasha Little; Qing Chang; Wei-Shen Chen; Khalida Wani; Mariana Petaccia De Macedo; Eveline Chen; Jacob L Austin-Breneman; Hong Jiang; Jason Roszik; Michael T Tetzlaff; Michael A Davies; Jeffrey E Gershenwald; Hussein Tawbi; Alexander J Lazar; Patrick Hwu; Wen-Jen Hwu; Adi Diab; Isabella C Glitza; Sapna P Patel; Scott E Woodman; Rodabe N Amaria; Victor G Prieto; Jianhua Hu; Padmanee Sharma; James P Allison; Lynda Chin; Jianhua Zhang; Jennifer A Wargo; P Andrew Futreal
Journal:  Sci Transl Med       Date:  2017-03-01       Impact factor: 17.956

5.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.

Authors:  Willy Hugo; Jesse M Zaretsky; Lu Sun; Chunying Song; Blanca Homet Moreno; Siwen Hu-Lieskovan; Beata Berent-Maoz; Jia Pang; Bartosz Chmielowski; Grace Cherry; Elizabeth Seja; Shirley Lomeli; Xiangju Kong; Mark C Kelley; Jeffrey A Sosman; Douglas B Johnson; Antoni Ribas; Roger S Lo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

6.  Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

Authors:  Stefani Spranger; Robbert M Spaapen; Yuanyuan Zha; Jason Williams; Yuru Meng; Thanh T Ha; Thomas F Gajewski
Journal:  Sci Transl Med       Date:  2013-08-28       Impact factor: 17.956

7.  Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Authors:  Matthew M Gubin; Xiuli Zhang; Heiko Schuster; Etienne Caron; Jeffrey P Ward; Takuro Noguchi; Yulia Ivanova; Jasreet Hundal; Cora D Arthur; Willem-Jan Krebber; Gwenn E Mulder; Mireille Toebes; Matthew D Vesely; Samuel S K Lam; Alan J Korman; James P Allison; Gordon J Freeman; Arlene H Sharpe; Erika L Pearce; Ton N Schumacher; Ruedi Aebersold; Hans-Georg Rammensee; Cornelis J M Melief; Elaine R Mardis; William E Gillanders; Maxim N Artyomov; Robert D Schreiber
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

8.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.

Authors:  Nicholas McGranahan; Andrew J S Furness; Rachel Rosenthal; Sofie Ramskov; Rikke Lyngaa; Sunil Kumar Saini; Mariam Jamal-Hanjani; Gareth A Wilson; Nicolai J Birkbak; Crispin T Hiley; Thomas B K Watkins; Seema Shafi; Nirupa Murugaesu; Richard Mitter; Ayse U Akarca; Joseph Linares; Teresa Marafioti; Jake Y Henry; Eliezer M Van Allen; Diana Miao; Bastian Schilling; Dirk Schadendorf; Levi A Garraway; Vladimir Makarov; Naiyer A Rizvi; Alexandra Snyder; Matthew D Hellmann; Taha Merghoub; Jedd D Wolchok; Sachet A Shukla; Catherine J Wu; Karl S Peggs; Timothy A Chan; Sine R Hadrup; Sergio A Quezada; Charles Swanton
Journal:  Science       Date:  2016-03-03       Impact factor: 47.728

9.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Authors:  Shohei Koyama; Esra A Akbay; Yvonne Y Li; Grit S Herter-Sprie; Kevin A Buczkowski; William G Richards; Leena Gandhi; Amanda J Redig; Scott J Rodig; Hajime Asahina; Robert E Jones; Meghana M Kulkarni; Mari Kuraguchi; Sangeetha Palakurthi; Peter E Fecci; Bruce E Johnson; Pasi A Janne; Jeffrey A Engelman; Sidharta P Gangadharan; Daniel B Costa; Gordon J Freeman; Raphael Bueno; F Stephen Hodi; Glenn Dranoff; Kwok-Kin Wong; Peter S Hammerman
Journal:  Nat Commun       Date:  2016-02-17       Impact factor: 14.919
  9 in total
  10 in total

Review 1.  Engineered nanomedicines block the PD-1/PD-L1 axis for potentiated cancer immunotherapy.

Authors:  Jun-Hao Li; Lu-Jia Huang; Hui-Ling Zhou; Yi-Ming Shan; Fang-Min Chen; Vesa-Pekka Lehto; Wu-Jun Xu; Li-Qiang Luo; Hai-Jun Yu
Journal:  Acta Pharmacol Sin       Date:  2022-04-28       Impact factor: 6.150

Review 2.  p73 isoforms meet evolution of metastasis.

Authors:  Stella Logotheti; Athanasia Pavlopoulou; Stephan Marquardt; Işıl Takan; Alexandros G Georgakilas; Thorsten Stiewe
Journal:  Cancer Metastasis Rev       Date:  2022-08-11       Impact factor: 9.237

3.  Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R.

Authors:  Ying-Qiang Liu; Ya-Nan Wang; Xiao-Yun Lu; Lin-Jiang Tong; Yan Li; Tao Zhang; Qiu-Ju Xun; Fang Feng; Yu-Zhe Chen; Yi Su; Yan-Yan Shen; Yi Chen; Mei-Yu Geng; Ke Ding; Yan-Li Li; Hua Xie; Jian Ding
Journal:  Acta Pharmacol Sin       Date:  2018-07-03       Impact factor: 6.150

4.  Immune Cytolytic Activity Is Associated With Genetic and Clinical Properties of Glioma.

Authors:  Zhi-Liang Wang; Zheng Wang; Guan-Zhang Li; Qiang-Wei Wang; Zhao-Shi Bao; Chuan-Bao Zhang; Tao Jiang
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

5.  Capturing transient antibody conformations with DNA origami epitopes.

Authors:  Ping Zhang; Xiaoguo Liu; Pi Liu; Fei Wang; Hirotaka Ariyama; Toshio Ando; Jianping Lin; Lihua Wang; Jun Hu; Bin Li; Chunhai Fan
Journal:  Nat Commun       Date:  2020-06-19       Impact factor: 14.919

Review 6.  Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.

Authors:  Sama Rezasoltani; Abbas Yadegar; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Cancer Med       Date:  2020-12-25       Impact factor: 4.452

Review 7.  Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives.

Authors:  Chang Lu; Yi-Chen Zhang; Zhi-Hong Chen; Qing Zhou; Yi-Long Wu
Journal:  Front Oncol       Date:  2022-03-14       Impact factor: 6.244

8.  Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer.

Authors:  Xiaoqiang Qi; Feng Wu; Sung Hoon Kim; Jussuf T Kaifi; Eric T Kimchi; Helena Snyder; Anuradha Illendula; Todd Fox; Mark Kester; Kevin F Staveley-O'Carroll; Guangfu Li
Journal:  FASEB J       Date:  2022-04       Impact factor: 5.834

Review 9.  Biomarkers of immunotherapy in non-small cell lung cancer.

Authors:  Lingling Wang; Yue Hu; Shengchao Wang; Jiali Shen; Xiaochen Wang
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967

10.  Targeting CAMKII to reprogram tumor-associated macrophages and inhibit tumor cells for cancer immunotherapy with an injectable hybrid peptide hydrogel.

Authors:  Xiaomeng Dai; Jingshu Meng; Suke Deng; Lingling Zhang; Chao Wan; Lisen Lu; Jing Huang; Yan Hu; Zhanjie Zhang; Yan Li; Jonathan F Lovell; Gang Wu; Kunyu Yang; Honglin Jin
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.